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and more than 20 years after the first percutaneous
coronary angioplasty. The ideal revascularization strat-
egy should be safe and effective, provide the best imme-
diate and long-term result, be associated with minimal
morbidity and invasiveness, be inexpensive, and require
a short hospitalization.
In the past few years a rapid expansion of the avail-
able options for myocardial revascularization has
occurred both in the interventional cardiology and in
the cardiac surgery field (Table I); as a result, the gap
between percutaneous and surgical coronary revascu-
larization is narrowing, as percutaneous techniques
move from “plain old balloon angioplasty” to more
invasive and costly techniques1 and surgery is moving
toward less invasive and less expensive approaches.2
T he search for the optimal strategy for myocardialrevascularization is still in progress, 30 years after
the first coronary artery bypass graft (CABG) operation
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ALTERNATIVE APPROACH TO MULTIVESSEL CORONARY DISEASE WITH INTEGRATED CORONARY
REVASCULARIZATION
The successful and cost-effective application of min-
imally invasive CABG (MICABG)3,4 has created the
basis for a new approach to multivessel coronary artery
disease (CAD) by combining the minimally invasive
surgical revascularization of the left anterior descend-
ing coronary artery (LAD) using the left internal tho-
racic artery (LITA) with percutaneous coronary inter-
vention of the circumflex or right coronary artery.5,6
We hypothesized that integrated coronary revascu-
larization, defined as the combination of MICABG
and percutaneous coronary intervention, could provide
the best revascularization strategy for patients with
multivessel CAD involving the LAD, resulting in a
safe and efficacious treatment with the best possible
short- and long-term results at low cost and short hos-
pital stay. We describe in this report the results of a fea-
sibility study of integrated coronary revascularization
at a single center.
Methods
The first MICABG was performed at the University of
Pittsburgh in June 1995. Through May 1998, 189 procedures
have been performed; our angiographic patency for ITA anas-
tomosis is 97.7% (84/86 consecutive LITA angiographies
from September 1996 to September 1997).
Since September 1996, our Minimally Invasive Cardiac
Surgery Program joined forces with the Interventional
Cardiology group to evaluate the feasibility of integrated
coronary revascularization and explore its potential scope of
applicability.
A pilot study of 31 patients that met inclusion criteria for
integrated coronary revascularization (detailed in the Patient
selection section) was performed from September 1996 to
January 1998 at our center. The protocol was reviewed by the
Institutional Review Board of the University of Pittsburgh
and informed consent was obtained from all patients.
Patient selection. Criteria for inclusion in this study were
as follows: (1) multivessel CAD (>70% stenosis) involving
the LAD distribution with Canadian Cardiovascular Society
angina class III or greater; (2) LAD lesion not ideal for per-
cutaneous coronary intervention (type C American Heart
Association/American College of Cardiology classification7;
(3) circumflex and/or right coronary artery lesions suitable
for percutaneous coronary intervention (type A or B).
Patients were excluded if there was need for associated pro-
cedures (eg, carotid or valve disease).
In 1997 (January to December) our center performed 891
surgical coronary revascularizations, including 120
MICABGs. The relatively small number of patients found eli-
gible for inclusion in this study (31 patients over 15 months
from September 1996 to January 1998) can be explained by
the low level of awareness for integrated coronary revascu-
larization by our referring cardiologists and by the absence of
a systematic screening for eligible patients.
Patient characteristics are listed in Table II.
Revascularization strategy. Every candidate for integrated
coronary revascularization was discussed by an interdiscipli-
nary team composed of the referring cardiologist, an interven-
tional cardiologist (H.A.C.), and a cardiac surgeon with expe-
rience in MICABG (M.Z. or B.P.G.). The procedure
committee determined the revascularization strategy on the
basis of the angiographic extent of CAD, patient preferences,
and alternative options. A decision was reached by group con-
sensus. In case of left main CAD, MICABG was always per-
formed first, to protect the left main coronary artery for the
percutaneous coronary intervention8; for the other patients,
the particular procedural sequence was selected on the basis of
logistic considerations (catheterization laboratory and operat-
ing room schedule). When possible, integrated coronary
revascularization was performed during the same day.
Study end points. End points were considered death,
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Table I. Myocardial revascularization strategies
Percutaneous coronary intervention
Percutaneous transluminal coronary angioplasty
Stenting
Atherectomy
Laser angioplasty
Percutaneous transmyocardial laser revascularization
Combination of the above
Surgical revascularization
CABG
MICABG
Transmyocardial laser revascularization 
Integrated coronary revascularization (MICABG + PTCA/stent)
Table II. Patient characteristics (n = 31)
Age (y) 69 (46-86)
Age > 75 y 13 (42%)
Male 22 (71%)
Left ventricular ejection fraction (%) 46.3 ± 12
Left ventricular ejection fraction < 35% 6 (19%)
Unstable angina 23 (74%)
Recent (<48 h) myocardial infarction 5 (16%)
Urgent revascularization 5 (16%)
Parsonnet score > 20% 8 (26%)
Chronic obstructive pulmonary disease (%) 18 (58%)
Renal dysfunction 6 (19%)
Previous cerebrovascular accident 17 (55%)
Severe peripheral vascular disease 10 (32%)
Morbid obesity 11 (35%)
Non–insulin-dependent diabetes mellitus 8 (25%)
Insulin-dependent diabetes mellitus 0
Intra-aortic balloon pumping 2 (6%)
Congestive heart failure 4 (13%)
Extent of CAD:
One-vessel CAD 2 (7%)
Two-vessel CAD 15 (48%)
Three-vessel CAD 8 (26%)
Left main CAD 6 (19%)
CAD, Coronary artery disease.
myocardial infarction, residual angina, need for repeat revas-
cularization, and LITA patency.
Surgical technique. MICABG was performed through a 3-
inch left minithoracotomy in the fourth or fifth intercostal
space under direct vision of the surgeon, without removal of
any costal cartilage or rib. Intravenous infusion of diltiazem
(3-5 mg/h), as an ischemic preconditioning agent, was used
in all patients. The LITA was harvested circumferentially as
a pedicle for its entire length from the subclavian artery take-
off to the bifurcation (average length of LITA pedicle = 15
cm). A dedicated LITA retractor (CardioThoracic Systems
Inc, Cupertino, Calif) was successfully used and provided
excellent exposure of the entire bed of the LITA. The heparin
dose used was 100 IU/kg. The LITA–LAD anastomosis was
performed with the use of a mechanical stabilizer
(CardioThoracic Systems Inc) without pharmacologic brady-
cardia. The LITA anastomosis was performed with the use of
two separate 8-0 polypropylene sutures at the heel and toe
(“double parachute” technique). Before final tying of the
suture, the anastomosis was probed with a nonocclusive 1-
mm Parsonnet probe in three directions: proximal LAD, dis-
tal LAD, and proximal LITA; furthermore, the LITA was
flushed through the open suture line before final tying of the
knot to eliminate potential thrombus at the site of application
of the vascular occluder. On completion of the anastomosis,
the flow pattern of the LITA was analyzed intraoperatively
with a customized ultrasound transit-time flowmeter
(Transonic Systems Inc, Ithaca, NY) as previously
described.9 Extubation was attempted in all cases in the oper-
ating room. Postoperative pain control was achieved by a pre-
operatively placed epidural catheter or by intercostal nerve
block when an epidural catheter was contraindicated (eg,
with intravenous heparin infusion). Aspirin (325 mg once a
day) was started within 6 hours of MICABG. If percutaneous
coronary intervention included the placement of a stent,
patients also received ticlopidine (250 mg twice daily).
Angiographic confirmation of LITA-LAD anastomotic
patency was performed during the primary hospitalization.
Follow-up protocol included exercise or pharmacologic stress
thallium myocardial scintigraphy at 1 month and Doppler
echocardiography of LITA flow10 and physical examination
at 1, 6, and 12 months’ follow-up.
Definitions. The goal of integrated coronary revasculariza-
tion was revascularization of all viable myocardial territories
served by one of the three major coronary arteries (LAD, cir-
cumflex artery, right coronary artery) with a coronary steno-
sis greater than 70% of the reference diameter and a target
vessel with a diameter greater than 1.5 mm. Patients were
divided in two groups: group A included patients who
received an anatomically complete revascularization and
group B those with an anatomically incomplete but function-
ally adequate revascularization (ie, revascularization of non-
viable myocardium or areas served by a target vessel < 1.5
mm of diameter was not performed).11
Statistical analysis. Data were expressed as mean ± stan-
dard deviation. Group comparisons were performed by
means of Fisher’s exact test.
Results
Integrated coronary revascularization was performed
in all 31 patients without mortality. During MICABG,
LITA was anastomosed to the LAD in 28 patients, to
the diagonal branch of the LAD in 2 patients (because
of a diffusely diseased LAD in 1 patient and intramy-
ocardial LAD in the other), and to both the LAD and
diagonal as a Y graft using the left radial artery in 1
patient. The time to complete the LITA anastomosis
was 14.6 ± 5.2 minutes and the operating time (skin to
skin) was 105 ± 20 minutes; 28 patients were extubat-
ed in the operating room (28/31 = 90%) and the
remaining 3 were extubated within 2 hours. No patient
required re-exploration for bleeding or conversion to
sternotomy. There were no perioperative myocardial
infarctions. Two patients with left main coronary artery
stenosis had an intra-aortic balloon pump already in
place at the time of MICABG. One patient had under-
gone a previous left lower lobectomy. One patient had
undergone previous CABG with occluded vein grafts.
One patient had idiopathic thrombocytopenia (platelet
count 15,000/mm2) but did not require platelet transfu-
sion during or after MICABG.
Only 1 patient had atrial fibrillation after the opera-
tion (1/31 = 3%). Two patients (2/31 = 6.4%) required
transfusion of packed red blood cells. LITA anastomo-
sis was confirmed to be patent by angiography (26
patients) or intraoperative LITA flow pattern analysis9
(5 patients) in all patients (100%; 95% confidence lim-
its = 0.89-1). In both patients in whom the LITA was
anastomosed to the diagonal branch, the LAD was ret-
rogradely filled without restriction by the LITA at fol-
low-up angiography. 
Details of percutaneous coronary intervention are
listed in Table III. Percutaneous coronary intervention
was performed before MICABG (1 day before in 1
case and 2 days before in the other) in 2 patients (7%),
on the same day of MICABG in 16 patients (52%), on
postoperative day 1 in 3 patients (9%), and on postop-
erative days 2 to 4 in 10 patients (32%). In 1 patient
who required abciximab during stent placement,
MICABG was performed 2 days later to avoid bleeding
complications.
Overall, integrated coronary revascularization allowed
a revascularized vessel/patient ratio of 2.26. Post-
procedure length of stay in the hospital was 2.7 ± 1.0
days, and 13 patients (42%) were discharged home on
postoperative day 1 or 2.
The degree of revascularization achieved was
anatomically complete in 21 patients (21/31 = 68%;
group A) and anatomically incomplete but functionally
adequate in 10 patients (10/31 = 32%; group B).
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Anatomically complete revascularization was achieved
more frequently in patients with lower preoperative risk
profile (Parsonnet score12 < 20%) (18/23 = 78%) than
in patients with higher risk (Parsonnet > 20%) (3/8 =
37.5%) (P = .07; Fisher’s exact test, 2-tailed).
Three patients (9.6%) required repeat target ves-
sel revascularization. One patient who underwent
MICABG and stent of the obtuse marginal branch of the
circumflex coronary artery had a subacute thrombosis
of the obtuse marginal stent 4 days after the procedure
because of noncompliance with the aspirin/ticlopidine
regimen. She underwent percutaneous transluminal
coronary angioplasty (PTCA) of the thrombosed stent
that eventually restenosed requiring single-vessel
CABG to the obtuse marginal branch; at operation, the
LITA-LAD anastomosis was widely patent. Another
patient had new critical disease proximal to a non-
stenotic right coronary artery stent 3 months after inte-
grated coronary revascularization; he underwent new
stent placement of the proximal right coronary artery
without complications. The third patient had new sig-
nificant disease develop proximal to a stent of the distal
obtuse marginal branch in a diffusely diseased vessel 6
months after integrated coronary revascularization and
required deployment of 2 additional stents to the proxi-
mal circumflex artery. One of these patients requiring
repeat revascularization was in group A (anatomically
complete revascularization) (1/21 = 5%) and 2 patients
were in group B (incomplete but functionally adequate
revascularization) (2/10 = 20%).
Excluding the 3 patients requiring repeat revascular-
ization, adenosine stress thallium myocardial scintigra-
phy was performed in 21 patients (21/28 = 75%) and
was negative for the presence of reversible ischemic
defects. Noninvasive Doppler assessment of LITA10
demonstrated maintained patency of the anastomosis
up to 10.8 months of follow-up in all patients.
Results are summarized in Table IV.
Discussion
The last few years have witnessed a significant
expansion of the therapeutic options available for
patients with CAD requiring myocardial revasculariza-
tion. Meta-analysis of recent major trials have shown
that PTCA and CABG are associated with no differ-
ence in major adverse cardiac events.13 However,
PTCA is associated with a higher need for repeat revas-
cularization caused by restenosis.14 Furthermore, there
is evidence from randomized studies that restenosis is
higher in the LAD than in non-LAD lesions. Patients
enrolled in the CAVEAT (Coronary Angioplasty Versus
Excisional Atherectomy Trial) study15 with proximal
LAD stenosis had a 63% restenosis rate after PTCA,
compared with a 50% restenosis rate in non-LAD
lesions. In the Stent ReStenosis Study (STRESS),16 in
which LAD lesion location was compared with non-
LAD lesion location at the time of intervention, the
vessels in the LAD group were smaller (2.85 ± 0.4 mm
vs 3.09 ± 0.4 mm; P < .001), with less acute coronary
lumen gain after intervention (1.3 ± 0.49 mm vs 1.57 ±
0.5 mm; P < .001), which translated into a smaller
mean luminal diameter at follow-up (1.46 ± 0.6 mm vs
1.76 ± 0.6 mm; P < .001), and a higher diameter steno-
sis (48.85% ± 19.03% vs 42.9% ± 18.7%; P < .001).
The target vessel revascularization rate of patients with
LAD lesions treated was 19% versus 11% in the non-
LAD lesion location. In the PTCA group, the lesions in
the LAD location had a binary restenosis rate of 62%
compared with 32% in the non-LAD location. The
introduction of stents has decreased overall restenosis
rate to 31.6% in STRESS and 22% in the Belgium
442 Zenati, Cohen, Griffith The Journal of Thoracic and
Cardiovascular Surgery
March 1999
Table III. Percutaneous coronary interventions 
Patients (%)
Target vessels
RCA 9 (29%)
CX 9 (29%)
OM 9 (29%)
LMCA 4 (13%)
Diagonal 3 (10%)
Ramus 2 (6%)
Posterolateral branch of RCA 2 (6%)
Interventricular posterior coronary artery 1 (3%)
Extent of percutaneous coronary intervention
Single vessel 24 (77%)
Double vessel 6 (19%)
Triple vessel 1 (3%)
Type of percutaneous coronary intervention
Elective stent 23 (60%)
“Plain old balloon angioplasty” 13 (34%)
Rotational atherectomy + PTCA 2 (6%)
PTCA, Percutaneous transluminal coronary angioplasty; RCA, right coronary
artery; Ramus, ramus intermedius; OM, obtuse marginal; CX, circumflex;
LMCA, left main coronary artery.
Table IV. Results (mean follow-up = 10.8 mo)
Survival 100% (31/31) [CL = 0.89-1]
Freedom from angina/MI* 100% (31/31) [CL = 0.89-1]
LITA patency 100% (31/31) [CL = 0.89-1]
Freedom from repeat 90.4% (28/31) [CL = 0.74-0.98]
revascularization
CL, 95% Confidence limits; LITA, left internal thoracic artery; MI, myocardial
infarction.
*After repeat revascularization in 3 patients.
Netherlands Stent Study Group (BENESTENT ),17 but
recent data from the Washington Hospital Center show
that LAD location is still a major factor affecting loss
index after stenting (M. Leon, personal communica-
tion, September 1998).
The LAD is a strategically important artery, and the
patency of the LAD is an important determinant of sur-
vival because of the large territory of myocardium sup-
plied (up to 70% of the left ventricle).18 Revascular-
ization of the LAD with the LITA is associated with
improved survival (86.6% vs 75.9% actuarial survival
at 10 years; P < .001), freedom from cardiac events,
and long-term graft patency compared with CABG
with only saphenous vein grafts.19 The favorable
effects on mortality and morbidity are observed irre-
spective of age, gender, or left ventricular function.20
Prospective studies comparing CABG and medical
therapy have suggested that revascularization does not
necessarily improve survival in patients with single- or
double-vessel CAD unless one of the vessels is the
proximal LAD.21 Presence of atherosclerotic lesions in
non-LAD vessels affects the event rates of patients with
vein grafts but not of patients with LITA grafts.20
Cameron and associates22 observed that a durable arte-
rial graft to the LAD is a more powerful predictor of
survival than is progressive coronary atherosclerosis in
other coronary arteries. A unique feature of LITA used
as a bypass conduit is a striking resistance to atheroma,
with 10 years’ patency well above 90%. The LITA is
also able to dilate in vivo,23 physiologically adapting to
the flow requirement of the myocardium.
CABG with the LITA is clearly the revascularization
modality of choice for the LAD. With the introduction
of MICABG, the prognostic benefits of surgery may
now be gained without the drawbacks of sternotomies,
leg wounds, and cardiopulmonary bypass. We have
demonstrated that MICABG reduces mortality, cere-
bral events, and length of stay in extremely high-risk
patients.24 MICABG was also found to be associated
with significantly decreased need for repeat revascular-
ization compared with stenting for type C lesions of the
LAD.25 The major limitation of MICABG appears to
be the inaccessibility of the circumflex and right coro-
nary arteries. Standard CABG with saphenous vein
grafts to these coronary vessels is associated with a
patency of 60% at 10 years and freedom from saphe-
nous vein graft disease in only 50% of grafts.26
In an attempt to offer the best revascularization strat-
egy to patients with multivessel CAD, we hypothesized
that integrated coronary revascularization, by combin-
ing MICABG of the LAD with the LITA and percuta-
neous coronary intervention with predominant use of
stents, could provide “the best of two possible worlds,”
promoting a complementary role of minimally invasive
surgery and interventional cardiology.
In our series of 31 consecutive patients undergoing
interventional coronary revascularization, the acute
procedural success rate was 100%. Freedom from
repeat revascularization at 10.8 months’ follow-up is
90.4%; one case of subacute thrombosis owing to non-
compliance with aspirin/ticlopidine regimen occurred,
and 2 cases of recurrence of CAD proximal to the site
of stent placement were noted. No clinical restenosis
was observed. Patency of the LITA-LAD anastomosis
was 100%. Survival is 100% at 10.8 months. Unlike
Angelini and colleagues,5 we did not observe increased
bleeding caused by the more intense anticoagulation
required for stents.
In conclusion, on the basis of these early results, we
believe that integrated coronary revascularization is
feasible and safe. Since conventional CABG represents
a gold standard against which any new approaches to
coronary revascularization need to be tested, we have
designed the MORE trial; this is a prospective random-
ized trial comparing integrated coronary revasculariza-
tion and CABG for suitable patients with multivessel
CAD involving the LAD.
We agree with a recent editorial of Simoons27 that it
is reasonable for the future to envision the formation of
a practical “partnership” between interventional cardi-
ology and coronary bypass surgery, with the develop-
ment of revascularization centers in which different
procedures are performed by a closely coordinated team
of operators with different backgrounds.
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Discussion
Dr Steven W. Guyton (Seattle, Wash). It is important for
all of us to realize that there will be pressure from our cardi-
ologist colleagues to do this type of hybrid procedure, or per-
haps I should call it a “bastardized” procedure. In truth, many
such procedures will be done. It is important that this type of
procedure be studied, and I welcome having surgeons in-
volved in studying them.
You report on 31 consecutive patients, who actually should
be called 31 highly selected patients: they had 70% stenosis of
the LAD and other coronary arteries, class III or IV angina or
what was termed objective evidence of ischemia, their non-
LAD lesions were type A or B for percutaneous coronary
intervention, and they had no associated procedures. Fifty-five
percent of these patients had prior strokes; 35% of them were
morbidly obese. Every candidate was discussed by an inter-
disciplinary team, and I am encouraged that a surgeon was
included in that interdisciplinary team. How many patients
were discussed by this team to arrive at these 31 patients?
Dr Zenati. These 31 patients were the only ones who ful-
filled the inclusion criteria we set at the beginning of the
study. Early on, the awareness of this option was not wide-
spread among our cardiologists, and we did not systematically
screen patients for eligibility in this study.
Dr Guyton. How many coronary bypasses and angioplas-
ties were done during that same period?
Dr Zenati. In a 12-month period, we usually do about 900
CABGs.
Dr Guyton. Would you say that 5% of patients are appro-
priate for this sort of procedure?
Dr Zenati. I would think that it would be a much larger
percentage. A lot of these patients currently have multivessel
stenting instead of integrated revascularization.
Dr Guyton. You talk about multivessel disease, but in per-
cutaneous interventions only a single vessel was done in 97%
of the patients. The total number of revascularizations done in
these 31 patients was 64, I believe, for an average number of
2 revascularizations per patient.
Dr Zenati. The average number of revascularizations per
patient is actually 2.3.
Dr Guyton. Essentially, then, you are treating double-vessel
disease.
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Dr Zenati. Most of our patients had double-vessel disease,
but a quarter had triple-vessel disease.
Dr Guyton. Integrated coronary revascularization seems to
me to be a convenient way to achieve complete revascular-
ization in patients who refuse to consider a sternotomy or in
patients in whom the surgeons consider a sternotomy to be
too dangerous. Alternatively, integrated coronary revascular-
ization gives “functionally adequate” results in patients with
more diffuse disease who again are considered too high a risk
for CABG.
Diabetes is not mentioned in the paper. Did any of these
patients have diabetes?
Dr Zenati. About 25% had diabetes, but none of them had
insulin-dependent diabetes.
Dr Guyton. One of the things you might want to consider
in your randomized study is excluding patients with diabetes,
because of the long-term poor results with angioplasty.
Dr Zenati. Yes, you are referring to the results of the
Bypass vs. Angioplasty Revascularization Investigation trial,
and you are probably aware of the controversy concerning the
influence of diabetes on results of percutaneous intervention.
That is the reason that the BARI II trial was designed. 
Dr Guyton. It certainly may be a confounding factor,
though, in looking at your randomized trial. You point out the
narrowing gap between percutaneous intervention and surgi-
cal revascularization in terms of invasiveness and cost.
Outcome data, however, are comparable only in fairly short-
term results. Your goal of revascularization brings out a fairly
disturbing concept of “functionally adequate,” in which you
are revascularizing down to vessels at 1.5 mm in areas where
you can demonstrate ischemia. This was stated as the only
goal of your randomized trial when I looked up the protocol
on the Internet. You talked in your paper about the best pos-
sible short- and long-term results; yet the maximum results in
your paper are about 20 months, with average results at 10
months. Your myocardial optimal revascularization trial pro-
poses only a 1-year follow-up, which I find very disturbing.
Also, no end points are defined that would measure late
revascularization failures.
In this era, as the moving target of surgical revasculariza-
tion is coming to arterial grafts with improved results in a
second decade after CABG, I think it is important to compare
the best available hybrid procedure that you want to recom-
mend or want to study to the best available surgical option,
that of arterial revascularization.
Dr Zenati. I appreciate your comments, and certainly we
are aware of the importance of long-term results in a revas-
cularization study. The trial that we are setting up is based on
the funding we had available, which allows a 1-year follow-
up, but that is not saying that a longer follow-up would not be
necessary. Regarding the controversy between “anatomically
complete” and “functionally adequate,” I would like to stress
that our approach is not different from what we do every day
in the operating room. If we have a patient with a previous
transmural inferior myocardial infarction and occluded right
coronary artery, we do not feel guilty in not bypassing the
posterior descending artery; although in this setting we are
not performing complete revascularization, we believe that it
is functionally adequate for the patient.
Dr Guyton. Long-term results are best in patients whom
we consider to be completely revascularized. I find it disturb-
ing, therefore, that you state that your goal is to achieve
“functionally adequate” revascularization rather than com-
plete revascularization.
Dr Zenati. I agree with you that revascularization should
be as complete as possible, but I think the whole issue of
completeness of revascularization is a matter of definition.
Dr Vaughn A Starnes (Los Angeles, Calif). I too think this
study needs to be done. We know the operation is no better
than its weakest link. What discussions go on before placing
a patient in this protocol in terms of if it is a vessel that can
undergo PTCA and stent with reliable results? As we see your
short-term results, we have 3 patients coming to re-interven-
tion, 1 patient with CABG with a vein graft, which I assume
was done on bypass.
Dr Zenati. Yes.
Dr Starnes. Two more came back for re-intervention with
repeat stenting, and history tells us that those procedures will
likely fail too and require a repeat bypass operation. What
goes into the team evaluation of a particular lesion in terms of
whether the vessel can be opened reliably with PTCA and get
acceptable long-term results? Long-term results and multiple
stents in a single artery would argue against a long-term sat-
isfactory outcome. These patients, rather than being random-
ized, should have CABG.
Dr Zenati. I agree. In fact, we excluded patients with type
C lesions from percutaneous intervention. We think that for
patients with type A or B lesions percutaneous intervention
yields very good results. We do not think the integrated
approach will be replacing any existing alternative revascu-
larization available, but we think it will have a role for select-
ed patients, specifically the C lesions of LAD and type A/B
lesions of non-LAD vessels.
Dr Steven R. Gundry (Loma Linda, Calif). I appreciate
your bringing this hybrid procedure to our memberships’
attention, but I have a real problem with taking essentially
two inferior procedures, combining them, and promoting
them as a better procedure. I have a problem with saying that
you have 100% patency of the LAD anastomosis at 1 day or
at 1 hour, projecting that, and saying that at 1 year the anas-
tomoses are still patent. In our study of off-bypass patients,
it actually took approximately 21⁄2 years for the problems
with the anastomoses to surface. In fact, all of our patients
had negative stress tests after the operation, proving that the
anastomoses were patent at that time. To claim in your arti-
cle that you have 100% patency at 1 year’s follow-up when
your angiogram was done at 1 day is deceptive. Second, to
say that you have 100% angina-free patients at 1 year, and
yet 10% of them have had to have a re-intervention, is also a
bit deceptive.
Can you tell us how many patients have returned to any
form of anti-anginal therapy during that 1-year period?
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Dr Zenati. To answer the first question about the angiog-
raphy, the control studies were done early, but we also do a
follow-up study of flow pattern using Doppler echocardiog-
raphy. In all of those patients, patency was confirmed at fol-
low-up (maximum 10 months). 
About 30% of patients are receiving calcium channel
blockers if they have a history of hypertension.
Dr Gundry. Thank you. I do not think this discussion
would be complete without addressing cost, because we must
take into account the cost of multiple stents and redo stents.
A 10% failure rate is considered to be a failure of the
approach, which must be accounted for, and the cost of the
operating room and the surgical approaches must be consid-
ered, as well.
Have you analyzed the cost of this approach as an entity in
these 30 patients?
Dr Zenati. That is one of the main end points that will be
addressed by the trial. There are also several ways one could
think of optimizing costs, such as single operating room and
single cross-trained nurses. We currently do the procedures
the same day in two different rooms, and this does not really
alter the schedule too much. However, as you pointed out cor-
rectly, cost is going to be an issue and we are very interested
in evaluating that.
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